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Introduction
Since the discovery of cell-free fetal DNA (cffDNA) in
maternal plasma in 19971 there has been rapid progress in
harnessing this as a source of fetal genetic material for pre-
natal diagnosis. The majority of cell-free DNA (cfDNA) is
maternal in origin2, with the fetal proportion emanating
from the placenta3, detectable in the maternal circulation
from around 5weeks’ gestation2 and constituting around
only 10% of cfDNA in early pregnancy4. However, as
cffDNA is cleared rapidly from the maternal circulation
after delivery, it offers great potential as a source of fetal
genetic material for prenatal diagnosis5. Initially, in view
of the high background of maternal cfDNA, technological
restrictions only enabled the detection or exclusion of alle-
les that were not present in the mother but were present in
the fetus because they were paternally inherited or arose
de novo at conception. Thus, early indications were for
fetal sex determination using Y-chromosome alleles6,f e t a l
Rhesus D (RhD) genotyping in RhD-negative mothers7,8
or for the diagnosis of certain genetic conditions, such as
achondroplasia9, in which the majority of cases arise as a
result of a new mutation. Technological advances associ-
ated with the development of next-generation sequencing
(NGS) have enabled accurate counting of DNA sequences
that are associated with speciﬁc chromosomes10,11 present
in maternal blood, which has allowed very rapid devel-
opment of non-invasive prenatal testing (NIPT) for
aneuploidy12. Furthermore, quantiﬁcation of cffDNA
mayalsobeusefulintheearlyidentiﬁcationofpregnancies
at risk of other adverse outcomes, such as pre-eclampsia
and fetal growth restriction (FGR)13,14.
These developments are delivering the biggest change
seen in antenatal care over the last few decades, as the
need for invasive diagnostic testing reduces dramatically.
It is also likely that they will impact on the need for
some therapeutic interventions, such as in-utero fetal
transfusion, as well as offering a new diagnostic tool in
fetal medicine for diagnosis of a dysmorphic fetus and
earlier diagnoses in pregnancies at prior risk of a genetic
disorder. Here, we review the potential of cffDNA,
highlighting its use in fetal medicine, and discuss how it
is impacting on the practice of fetal medicine.
X-linked disorders and disorders of genital ambiguity
The earliest clinical use of cffDNA was for the determina-
tion of fetal sex1. This relies on the detection of sequences,
SRY or DYS14, in the maternal plasma that derive from
the Y-chromosome. The technique has already become
incorporated into standard care in several European
countries, including the UK, for management of pregnan-
cies at risk of severe X-linked genetic disorders15,16,s u c h
as Duchenne muscular dystrophy. It has the potential to
reduce the incidence ofinvasivetesting for such conditions
by up to 50% by allowing targeted testing in male-bearing
pregnancies16. In pregnancies at risk of congenital adrenal
hyperplasia, determining fetal sex can enable early ces-
sation of steroid treatment in male-bearing pregnancies
or, as occurs in several centers, steroid administration
could be delayed until fetal sex is determined through
early cffDNA testing and only offered in pregnancies in
which the fetus is known to be female17. However, close
co-ordination with fetal-medicine services is required
as testing is only reliable after 7weeks’ gestation, with
false-positive results possible in twin pregnancies or in
those with early fetal demise of a cotwin16.
Ambiguity of the genitalia is a rare ﬁnding on
ultrasound, and even with the advent and improvement
of three-dimensional (3D) imaging techniques, differen-
tiation between clitoromegaly in the female fetus and
hypospadias in the male remains difﬁcult (Figure1). In
cases in which genital ambiguity is isolated and cffDNA
testing indicates that the fetus is male, the most likely
diagnosis is hypospadias, although some rare endocrine
disorders cannot be excluded completely without
sequencing of the androgen receptor gene (Table1). If,
however, cffDNA testing indicates that the fetus is female
genetically, referral to a team specialized in disorders of
sexual development is advised as abnormalities in SRY
can cause disorders of sexual differentiation and multiple
markers should be assessed for determination of fetal sex
in these cases (Table1)15. Another relatively common
association with hypospadias is FGR; therefore, maternal
uterine artery Doppler examinations should be performed
and, if Down syndrome screening is performed, maternal
serum biomarker results should be reviewed for low levels
of pregnancy-associated plasma protein A (PAPP-A) and
high levels of human chorionic gonadotropin (hCG) or
α-fetoprotein levels (Table1).
The use of cffDNA for sex determination can be
an extremely useful aid to sonographic diagnoses of a
number of genetic syndromes that present with multiple
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Figure 1 Genital ambiguity in a male fetus (a), as evidenced by ampliﬁcation (arrow) of SRY sequences in cell-free fetal DNA (cffDNA) (b),
and in a female fetus (c), in which there is ampliﬁcation only of the control DNA sequences (d). PCR, polymerase chain reaction;
Rn, normalized reporter.
abnormalities, usually genital ambiguity in which deter-
mination of genetic sex can be diagnostic when combined
with the presence of other relevant sonographic ﬁndings
(Table2). For example, in cases of campomelic dysplasia,
which presents with varying degrees of lower limb
shortening and bowing, talipes and micrognathia, at least
50% of affected male fetuses have genital ambiguity or
complete sex reversal. Therefore, if a fetus has ambiguous
or female genitalia with these sonographic features and
cffDNA testing indicates a genetic female, the diagnosis
can be made (Table2 and Figure2). Non-invasive fetal
sex determination using cffDNA can also be very useful
in the presence of some urogenital anomalies, such as
bladder cloacal exstrophy, as knowledge of the genetic sex
can aid counseling with regard to long-term outcome18.
Cell-free fetal DNA and management of complications
arising from blood-group antigens
The second clinical application of cffDNA testing was
for the determination of fetal RhD status in pregnant
RhD-negative mothers19. As with fetal sex determination,
this is possible because an RhD-negative mother does not
produce any copies of the RhD gene (RHD), and thus
the RHD identiﬁed in maternal blood originates from
the fetus who has inherited the gene from the father. For
the past decade, fetal RHD genotyping in RhD-negative
women with signiﬁcant titers of anti-RhD immunoglob-
ulin has been possible using labor-intensive polymerase
chain reaction (PCR)-based methods19,20. This approach
to management of these high-risk pregnancies has avoided
the need for invasive testing that was required previously.
In addition to avoiding the associated risks of miscarriage,
NIPT circumvents the need for assessment of paternal
phenotype, which may not be known or available. If the
fetus is RhD positive, increased surveillance in a tertiary
center to monitor for the development of fetal anemia
or hydrops is required, whereas if the fetus is predicted
to be RhD negative, there is no risk of hemolytic disease
of the newborn (HDN) and standard antenatal care is
appropriate21.
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Table 1 Clinical management of fetuses with isolated genital ambiguity based on the cell-free fetal DNA (cffDNA) result
cffDNA result Differential diagnosis Other aids for management
Male Isolated hypospadias
FGR
Inadequate production of testosterone because of Leydig
cell hypoplasia or rare abnormalities of steroid
metabolic pathway
Partial androgen insensitivity syndrome
5α-reductase deﬁciency
True hermaphrodite
Look for markers of FGR:
review PAPP-A, hCG and MSAFP results if available
Review maternal Doppler
Consider referral to DSD team for sequencing of androgen
receptor gene
Female Congenital adrenal hyperplasia
21-hydroxylase deﬁciency
11-hydroxylase deﬁciency
3β-hydroxysteroid dehydrogenase deﬁciency
True hermaphrodite
Maternally derived androgens (e.g. luteoma of pregnancy)
Placental aromatase deﬁciency
Refer to DSD team for further investigations
Amniotic steroid levels
Maternal serum androgen levels
Maternal urinary estrogen levels
Maternal ovarian scan for multicystic change
DSD, disorders of sexual development; FGR, fetal growth restriction; hCG, human chorionic gonadotropin; MSAFP, maternal serum
alpha-fetoprotein; PAPP-A, pregnancy-associated plasma protein A.
Introduction of high-throughput technologies for mass
fetal RHD genotyping22 has provided potential for
routine fetal genotyping and targeted administration
of anti-D immunoglobulin, a human blood product.
Currently, many countries offer routine antenatal prophy-
laxis to all RhD-negative mothers. This has signiﬁcantly
decreased the incidence of Rhesus sensitization, and cases
resulting in fetal anemia are now rare. However, this
policy results in the unnecessary administration of anti-D
immunoglobulin to around 38% of RhD-negative women
who are carrying a RhD-negative fetus23. Routine fetal
RHD genotyping and targeted anti-D prophylaxis have
been introduced recently into routine obstetric care at
26–28weeks’ gestation for RhD-negative women in The
Netherlands and Denmark24,25. However, a UK study has
shown that high-throughput RHD genotyping is highly
accurate from 11weeks’ gestation26. Introduction at this
earlier stage in pregnancy would result in further avoid-
ance of administration of anti-D immunoglobulin for
sensitizing events that occur in early pregnancy. Sub-
sequently, there have been calls for implementation of
high-throughput RHD genotyping into routine antena-
t a lc a r ei nt h eU K 27. Current routine immunoprophylaxis
programs do not achieve complete uptake as some women
decline anti-D immunoglobulin treatment. Routine fetal
RHD genotyping is likely to be very acceptable to
women28 and may improve immunoprophylaxis uptake,
thereby targeting women at highest risk, causing a further
decline in rates of alloimmunization and, subsequently,
the need for in-utero transfusion.
Although anti-RhD is the most common cause of
HDN, other antibodies, in particular anti-c and anti-K
(and less commonly anti-C and anti-E), are responsible
for an increasing proportion of cases. Unlike anti-D,
there is no prophylaxis, so the use of cffDNA as routine
screening is unlikely; however, it remains an important
investigation in sensitized pregnant women. The accuracy
of fetal genotyping in these cases approaches 100%,
thereby obviating the need for invasive testing in these
pregnancies21,29,30.
Fetal or neonatal alloimmune thrombocytopenia
(FNAIT) is caused by production of maternal
alloantibodies directed against paternally inherited
antigens present on fetal platelets21. Complications
include intracranial hemorrhage, occurring in up to 20%
of cases, which may cause severe long-term consequences
to the child. Until recently, in cases with a heterozygous
father, invasive testing was required to determine whether
the fetus was affected by FNAIT, which can occur only if
they are positive for human platelet antigen-1a (HPA-1a).
Analysis of cffDNA in maternal blood can detect the
HPA-1a gene31,32, which again avoids the need for
invasive testing in women with a heterozygous partner.
Non-invasive prenatal testing for monogenic disorders
The use of cffDNA in the detection of monogenic
disorders is considerably more challenging technically
than fetal RHD genotyping or sex determination and is
currently in clinical use only for the detection of alleles
that have arisen de novo at conception, for example,
achondroplasia9, or that are inherited from the father33.
In recessive or X-linked conditions for which the mother
also carries the mutant allele, the high background of
maternal mutation present in her plasma outweighs any
fetal mutation and thus methods reliant on the detection
of small differences in the ratio of mutant-to-wild-type
alleles are required. Accurate estimation of this ratio is
also dependent on the proportion of fetal DNA in the
maternal plasma, the fetal fraction, and this can only
be assessed consistently in male-bearing pregnancies as
it requires measurement of an allele not present in the
mother34,35 or by use of the differential methylation
in fetal and maternal DNA36; as yet, the reliability of
these methods for use in routine clinical practice requires
further development and evaluation. It is likely that this
will become possible universally in the future, perhaps by
exploiting the fact that fetal DNA is shorter than maternal
cfDNA37. In recessive conditions, whereby the parents
carry different allele mutations, exclusion or detection of
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t h ep a t e r n a la l l e l ec a nb eu s e dt or e ﬁ n et h er i s kt ot h e
fetus, excluding risk if the paternal allele is not detected
in maternal plasma and increasing risk if the paternal
mutation is identiﬁed. In the latter situation, an invasive
test is required to determine whether or not the fetus
has inherited the maternal allele. This has recently been
reported in conditions such as thalassemia38 and cystic
ﬁbrosis39.
Deﬁnitive diagnosis of achondroplasia9 and
thanatophoric dysplasia40 by NIPT has been avail-
able on a research basis since 2007 and was approved for
use in routine clinical practice in the UK in 2012. The
early tests were based on restriction-enzyme-digest-PCR
methodology, whereby mutations had to be tested for
individually. This is labor intensive, slow and costly,
and the results can be difﬁcult to interpret (Figure3).
The advent of NGS has allowed the development of
gene panels for use in NIPT33 that allow all possible
disease-causing mutations to be tested for simultaneously
and a digital result enables easier interpretation. This has
greatly enhanced the utility of NIPT for conditions such
as thanatophoric dysplasia, of which there are multiple
possible mutations and all cases arise de novo as this
is a lethal dominant condition. NIPT can be a very
useful aid to clinical management of skeletal dysplasias.
Thanatophoric dysplasia is detected increasingly in early
pregnancy when the differential diagnosis includes the
short-ribbed polydactyly syndromes and other autoso-
mal recessively inherited conditions associated with a
high recurrence risk41 (Table2), whilst thanatophoric
dysplasia is a new dominant mutation with a low
recurrence risk. If positive for thanatophoric dysplasia,
NIPT can deliver a deﬁnitive diagnosis without the need
for invasive testing and allows the option of a surgical
termination, as a postmortem will not be required.
Additionally, NIPT can allow the safe differentiation
of thanatophoric dysplasia from achondroplasia, both
of which arise from mutations in the ﬁbroblast growth
factor receptor 3 gene (FGFR3), but the former is lethal
and the latter is the most common viable short-stature
syndrome. Distinguishing between these two conditions
can be challenging as they have many common features,
such as frontal bossing, relative macrocephaly, short
limbs, bowing of the femora, small chest and short
ﬁngers giving rise to the ‘trident’ hand appearance;
these features are all more extreme in thanatophoric
dysplasia. NIPT can also offer safer diagnostic testing
in twin pregnancies with fetuses discordant for the
abnormalities as it permits a safe deﬁnitive diagnosis
whilst avoiding the risk of miscarriage of the normal
fetus. In addition, it allows for conservative management
of pregnancy in lethal conditions with no requirement
for termination of pregnancy. In cases presenting at risk
of achondroplasia late in pregnancy, NIPT allows for
deﬁnitive diagnosis and accurate parental counseling
without the risk of precipitating preterm labor. In all
cases, it also allows for an early, safe, non-invasive test
to exclude recurrence or inheritance of a paternal mutant
allele in future pregnancies. This can be performed from
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Figure 2 Features of campomelic dysplasia detectable on ultrasound include shortened ‘bowed’ limbs (a) and ambiguous genitalia (b).
9weeks’ gestation, earlier than invasive testing, which
cannot be performed safely until 11weeks42,43,a n dm u c h
earlier than an ultrasound scan for women not wanting
to put the pregnancy at risk by an invasive test.
The use of cffDNA for the diagnosis of monogenic
disorders has great potential. In the UK it has
been approved for use in clinical National Health
Service (NHS) practice to screen for mutations in the
FGFR3 (achondroplasia and thanatophoric dysplasia)
and FGFR2 (Apert syndrome) genes and for paternal
exclusion of common cystic ﬁbrosis mutations. With the
introduction of these safer tests we are seeing a dramatic
decrease in the use of invasive testing for monogenic
disorders (Table3), with a further decline in the likely
need for invasive testing as more non-invasive tests are
developed and validated.
Cell-free DNA testing for aneuploidy
The use of cfDNA testing for aneuploidy is bringing the
most radical change to the practice of fetal medicine. Early
attempts at providing NIPT for Down syndrome relied on
quantifying the amount of placenta-speciﬁc 4 (PLAC4)
in the maternal plasma44. This gene originates from
chromosome 21, is expressed only in the placenta and
is therefore fetal in origin. By detection of two separate
alleles in a 1:1 ratio, the fetus can be assumed to be
euploid. If there is duplication of an allele (because of
an extra copy of chromosome 21), the ratio will be
2:1 and the fetus can be assumed to be trisomic for
chromosome 21. Although groundbreaking, this initial
approach was ﬂawed as it required the identiﬁcation of
genetic differences in the parents and was therefore only
applicable in around 40% of pregnancies. The advent of
NGS brought a new approach that could be applied
universally. Rather than detection of a gene product
derived from chromosome 21, all DNA circulating in
maternalplasmaissequenced.This,bydeﬁnition,includes
both maternal and fetal DNA, and sequencing will
analyze the entire fetal and maternal genome. There are
three NGS-based approaches to NIPT for aneuploidy:
whole-genome NGS; targeted NGS; and single nucleotide
polymorphisms (SNPs). The whole-genome approach10
requires sequencing of cfDNA from maternal plasma
to generate millions of short sequence reads from the
whole genome. These are then mapped to a reference
human genome sequence to determine from which
chromosome the fragment is derived; the number of
fragmentsmappeduniquelytothechromosomeofinterest
are then counted and compared with the number of
counts obtained from other chromosomes. A variety of
bioinformatics algorithms have been developed10,45,46 to
determine whether there is an increase or decrease in the
expected number of counts around a set threshold which
is suggestive of aneuploidy; for example, if the fetus has
trisomy 21, more fragments from chromosome 21 will
be present than expected in maternal plasma. Alternative
NGS approaches involve the selective ampliﬁcation of
speciﬁc genomic loci on the chromosome of interest
followed by sequencing. This approach may be more
economical as the amount of sequencing required is
reduced but has the limitation that only the preselected
regions of interest can be studied and the development of
these tests is potentially more labor intensive12, although
it does allow estimation of fetal fraction. Early studies
validated this approach for the detection of trisomies 21
and 18 in high-risk pregnancies47 but, more recently,
the results of a large general-population study have
shown similar high performance in pregnancies at low
prior risk48. The third approach, a variation of the
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Figure 3 Detection of a mutation in the ﬁbroblast growth factor receptor 3 (FGFR3) gene causing thanatophoric dysplasia, showing the
increasing ease of interpretation between polymerase chain reaction (PCR)-based method (a), digital PCR (b) and digital readout obtained
from sequencing (c). PCR-based method (a) relies on subjective interpretation; very faint bands for mutant alleles in affected cell-free (cf)
DNA can be seen (bottom arrows). The wild-type (normal) allele is strongly present in all samples (upper arrow). This compares with digital
PCR (b) for detection of the mutant allele c.742C>T (blue dot) and wild-type alleles (red dot). Each row represents one sample. Wild-type
signals are present in all samples but the mutant allele is only present in the positive control (panel 1) and test sample (panel 2). Panel 3 is the
result obtained from a normal pregnancy and shows only wild-type alleles present. The digital readout obtained from sequencing (c) reveals
a very high wild-type allele count (blue), as this represents both maternal and fetal alleles, and a lower mutant allele (pink) count, but is still
very high compared with the counts for other disease-causing mutations, indicating that the fetus has thanatophoric dysplasia as a result of
the c.742C>T mutation.
targeted approach, is based on the ampliﬁcation of large
numbers of polymorphic loci (SNPs) on the chromosome
of interest49. Sensitivity and speciﬁcity for the detection
of common aneuploidies are high for whole-genome,
targeted and SNP approaches, irrespective of the
sequencing platform or bioinformatic algorithms used12.
Since the ﬁrst reports describing the use of NGS for
NIPT to detect trisomy 2110,11, the pace of development
has been extremely rapid and entirely commercially
driven. NIPT is now available in the private sector in
more than 50 countries, with detection rates in excess
of 99% for trisomy 21 and slightly lower for trisomies
18 and 13, at around 96% and 92%, respectively50,51.
Sensitivity for detection of sex-chromosome aneuploidy
remains lower, at 88.6%, with a false-positive rate of
0.12% for monosomy X50,51. NIPT for the detection of
aneuploidy has been shown to be a highly effective test in
both high-risk12 and low-risk48 pregnancies.
Although more accurate than conventional combined
screening (using nuchal translucency, PAPP-A and hCG)
in the ﬁrst trimester48, NIPT should still be regarded as
a highly sensitive screening test, rather than a diagnostic
one52–54, and any positive result should be conﬁrmed by
Table 3 Shift from invasive to non-invasive prenatal testing (NIPT)
for achondroplasia and thanatophoric dysplasia in the UK from
2009 to 2013, as tests became validated and approved for use in
the North East Thames Regional National Health Service genetics
laboratory
Achondroplasia Thanatophoric dysplasia
Year Invasive NIPT Invasive NIPT
2009–2010 28 0 16 0
2010–2011 27 13 21 0
2011–2012 28 14 25 2
2012–2013 20 22 17 11
2013– 10 14 7 18
Data are given as n. Other conditions for which NIPT has been
performed in high-risk families include Apert syndrome (n=7),
Crouzon syndrome (n=2), Fraser’s syndrome (n=4), autosomal
polycystic kidney disease, osteogenesis imperfecta (n=2) and cystic
ﬁbrosis.
invasive testing52–54, ideally by amniocentesis or, at min-
imum, karyotyping on cultured chorionic villi to avoid
conﬁned placental mosaicism. This is because of increas-
ing, well-documented evidence of discordant results
(mostly false positive, but false-negative results have also
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Figure 4 Detection of chromosomal rearrangements in cell-free
fetal DNA (cffDNA) using standard aneuploidy sequencing. A
small deletion ( ) of chromosome 2, conﬁrmed as 46,XY,del(2)
(p23p25.1), is indicated when the expected number of reads falls
outside a Z-score of±4( ).
been reported)55 between NIPT using cfDNA and conven-
tional karyotyping following invasive testing56.c f f D N Ai s
derived placentally and discordant results can therefore be
attributed to conﬁned placental mosaicism57,58 or to early
demise of an aneuploid cotwin (vanishing twin)55 as the
placenta can continue to shed cffDNA after death of the
fetus3. Other causes are derived maternally, including the
detection of maternal chromosomal rearrangements59–61
or mosaicism62 as sequencing analyzes maternal as well
as fetal cfDNA. Finally, maternal malignancy secondary
to a tumor secreting abnormal cell lines has also been
reported as the cause of a discordant NIPT result63.
Failure of NIPT or inconclusive results occur in up
to 5% of cases. These are usually caused by a low
fetal fraction of cffDNA50,51, most commonly because
of either testing at an early gestation, as the quantity
of cffDNA increases with placental mass and hence
gestation64,65, or high maternal body mass index64,65,
in which low fetal fraction has been attributed to high
levels of maternal cfDNA derived from adipose tissue. In
situations associated with a small placental volume, for
example, trisomies 13 and 1866,67, fetal fraction has been
reported to be lower.
NIPT for aneuploidy is now available widely across the
globe, albeit only in the private sector at present. The cost
of testing remains high but it has already decreased signif-
icantly and there is considerable debate as to how it might
be implemented into public-sector healthcare. It is likely
that different approaches will be taken depending on local
care pathways already in place and the local economy68.
However, at the moment, most commentators advocate
introduction of NIPT as a contingent test after traditional
Down syndrome screening69 and there are at least two
national studies ongoing in Europe evaluating different
approaches70,71. Although NIPT for aneuploidy is not yet
available outside the context of a research study in public
health services, widespread availability in the private
sector is having a signiﬁcant effect on the practice of fetal
medicine by decreasing the need for invasive diagnostic
testing.
Currently, NIPT can only be used reliably for detection
of the major trisomies and sex chromosome abnormalities
and, as such, will fail to detect the majority of other
chromosomal rearrangements that are the underlying
pathology in a signiﬁcant proportion of structurally
abnormal fetuses. However, how long this remains the
case is in question as there are already reports of NGS
detecting other chromosomal rearrangements. Initial
studies reported using very high depths of sequencing72
but, more recently, rearrangements detectable from the
karyotype have been detected using sequencing required
for standard aneuploidy detection (Figure4)73–75.
The main drawback with this approach is that the
false-positive rates and limits of detection are as yet
unknown, thus limiting its value at present. Despite this,
a number of companies have launched commercial tests
for a limited range of microdeletion syndromes, including
Di George (22q-), Wolf–Hirschhorn (4p-), Cri-du-Chat
(5p-), Prader–Willi, Angelman and 1p36-. These tests
have largely been developed using artiﬁcially produced
samples, and reasonable validation data describing
sensitivity, speciﬁcity and the positive predictive value
in maternal plasma samples are yet to be published.
Whilst this approach might increase the detection of
pathogenic mutations, this targeted approach will only
detect around 25% of pathogenic rearrangements as
these occur across all chromosomes. There is also concern
that using extended NIPT may increase the false-positive
rate, potentially reversing the downward trend seen in
invasive testing subsequent to the introduction of NIPT
for aneuploidy. If this approach is to be used, it would
seem sensible to conﬁne its use to cases in which there
is an increased incidence of pathogenic rearrangements,
for example in euploid fetuses with multiple ultrasound
anomalies76–78.
Conclusions
The use of cffDNA for the diagnosis of fetal genetic and
chromosomal conditions is having a profound effect on
the practice of fetal medicine worldwide. The advent of
NIPT for aneuploidy is reducing the need for invasive
testing, the rate of which has declined dramatically in
some countries79, a fall that is met with approval from
both women and health professionals alike as we move
toward safer and earlier prenatal diagnosis80,81.T h e
use of cffDNA to direct invasive testing or treatment
in sex-linked diseases is also decreasing the need for
invasive testing, whilst making prenatal diagnosis safer
and more acceptable to high-risk families82; however, this
may increase the economic burden on health services as
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an increasing number of families elect to undergo NIPT
for information83,84. These changes will inevitably impact
on care pathways and fetal medicine in general, in respect
to both training and service provision, as the indications
for invasive tests decrease. The pace of change has been
rapid and we must urgently address how we structure our
services so that we can provide safe services for those who
continue to need invasive testing and treatment.
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